Is Ind-Swift Labs. overvalued or undervalued?
As of April 17, 2025, Ind-Swift Labs. is considered attractive and undervalued with a PE ratio of 7.58, significantly lower than competitors like Sun Pharma and Divi's Lab, despite a year-to-date underperformance of -14.97%, but it has shown strong long-term growth with a 237.36% return over five years.
As of 17 April 2025, the valuation grade for Ind-Swift Labs. has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered undervalued, supported by key ratios such as a PE ratio of 7.58, an EV to EBITDA of 3.62, and a Price to Book Value of 0.60. These metrics suggest that Ind-Swift Labs. is trading at a significant discount compared to its peers.In comparison to industry competitors, Ind-Swift Labs. has a more favorable valuation than Sun Pharma, which has a PE ratio of 35.25, and Divi's Lab, with a PE ratio of 79.33. Other attractive peers include Cipla and Dr. Reddy's Labs, with PE ratios of 22.99 and 19.49, respectively. Notably, while Ind-Swift Labs. has underperformed the Sensex year-to-date with a return of -14.97% compared to the Sensex's 5.63%, its long-term performance over five years shows a robust return of 237.36%, reinforcing its potential for recovery and growth.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
